<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://peptidesagora.com/news/alopecia-market-hits-19-billion-jak-evolution</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Cosmo Phase 3 Data Triggers Regulatory Reset in $19 Billion Alopecia Market]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/alopecia-market-hits-19-billion-jak-evolution.jpg</image:loc>
      <image:title><![CDATA[Cosmo Phase 3 Data Triggers Regulatory Reset in $19 Billion Alopecia Market]]></image:title>
      <image:caption><![CDATA[Cosmo Pharmaceuticals announced positive Phase 3 topline data for clascoterone 5% topical solution in male androgenetic alopecia on September 2. This clinical milestone coincides with a DataM Intelligence forecast valuing the alopecia.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/biopharma-reverse-mergers-surge-rival-ipos</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Biopharma Reverse Mergers Rise 1,600% in Q3 to Rival IPOs]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/biopharma-reverse-mergers-surge-rival-ipos.jpg</image:loc>
      <image:title><![CDATA[Biopharma Reverse Mergers Rise 1,600% in Q3 to Rival IPOs]]></image:title>
      <image:caption><![CDATA[Seventeen biopharma reverse mergers were completed or planned in Q3 2026, a 1,600% increase over the single deal recorded in Q2. BioSpace data shows this volume nearly matches traditional IPOs as companies prioritize fixed valuations and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/bryan-johnson-autoimmune-diagnosis</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Bryan Johnson Autoimmune Gastritis Diagnosis Confirmed by New York Times]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bryan-johnson-autoimmune-diagnosis.jpg</image:loc>
      <image:title><![CDATA[Bryan Johnson Autoimmune Gastritis Diagnosis Confirmed by New York Times]]></image:title>
      <image:caption><![CDATA[The New York Times reported on August 21, 2026, that Bryan Johnson has autoimmune gastritis, a condition where the immune system attacks stomach lining. The diagnosis followed 11 years of unexplained low ferritin levels that extensive.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/dana-white-peptides-health-transformation</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[How Peptides Helped Transform Dana White’s Health: Inside Gary Brecka’s 10X Protocol]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/dana-white-peptides-health-transformation.jpg</image:loc>
      <image:title><![CDATA[How Peptides Helped Transform Dana White’s Health: Inside Gary Brecka’s 10X Protocol]]></image:title>
      <image:caption><![CDATA[Facing severe hypertension and metabolic syndrome, UFC CEO Dana White adopted a targeted peptide regimen with Gary Brecka. Here is the exact stack, the biological mechanisms, and what clinical science actually shows.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fluorescent-peptides-bioassays-nature</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Nature Chemistry Fluorogenic Peptides Enable Wash-Free PD-1 Bioassays in Live T Cells]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fluorescent-peptides-bioassays-nature.jpg</image:loc>
      <image:title><![CDATA[Nature Chemistry Fluorogenic Peptides Enable Wash-Free PD-1 Bioassays in Live T Cells]]></image:title>
      <image:caption><![CDATA[Researchers report a general strategy for multicolour fluorogenic amino acids using tryptophan-induced quenching. These probes enable wash-free PD-1 imaging in activated T cells and identified avasimibe as a small-molecule modulator in.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/glp-1-boom-peptide-synthesis-market-growth</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Import Alert 66-80 Defines Peptide Synthesis Market Boundaries]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glp-1-boom-peptide-synthesis-market-growth.jpg</image:loc>
      <image:title><![CDATA[FDA Import Alert 66-80 Defines Peptide Synthesis Market Boundaries]]></image:title>
      <image:caption><![CDATA[FDA Import Alert 66-80 created a verified supplier list for GLP-1 active pharmaceutical ingredients. Research and Markets projects the compliant peptide synthesis market will grow from $4.4 billion in 2026 to $7 billion by 2035. This.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/serena-williams-alcaraz-open-doubles</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Serena Williams and Alcaraz Accept U.S. Open Mixed Doubles Wild Card]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/serena-williams-alcaraz-open-doubles.jpg</image:loc>
      <image:title><![CDATA[Serena Williams and Alcaraz Accept U.S. Open Mixed Doubles Wild Card]]></image:title>
      <image:caption><![CDATA[Serena Williams and Carlos Alcaraz will partner in the 2026 U.S. Open mixed doubles tournament following a wild card acceptance confirmed August 22. While digital communities speculate on performance-enabling recovery stacks, The Athletic.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/ucla-peptide-marketing-vs-science</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[UCLA Health Review Finds Zero Randomized Controlled Trials for BPC-157 and TB-500]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ucla-peptide-marketing-vs-science.jpg</image:loc>
      <image:title><![CDATA[UCLA Health Review Finds Zero Randomized Controlled Trials for BPC-157 and TB-500]]></image:title>
      <image:caption><![CDATA[A September 2 review by UCLA Health identifies an absence of randomized controlled trials for BPC-157 and TB-500 in human cohorts. Researchers cite potential safety issues and unverified manufacturing standards despite widespread marketing.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/usada-weightlifter-peptide-suspension</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[USADA Reduces Jara MacDermott Ban to Two Years After Physician-Directed Testosterone Use]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/usada-weightlifter-peptide-suspension.jpg</image:loc>
      <image:title><![CDATA[USADA Reduces Jara MacDermott Ban to Two Years After Physician-Directed Testosterone Use]]></image:title>
      <image:caption><![CDATA[Jara MacDermott’s reduced sanction for physician-directed testosterone metabolites illustrates the gap between wellness clinic prescriptions and WADA strict liability in masters sport.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/zealand-pharma-petrelintide-buyback-momentum</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-02T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Zealand Pharma Initiates Petrelintide Phase 3 Trials Amid Week 35 Share Buyback Correction]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/zealand-pharma-petrelintide-buyback-momentum.jpg</image:loc>
      <image:title><![CDATA[Zealand Pharma Initiates Petrelintide Phase 3 Trials Amid Week 35 Share Buyback Correction]]></image:title>
      <image:caption><![CDATA[Zealand Pharma confirmed the initiation of Phase 3 registrational trials for petrelintide monotherapy in H2 2026 based on Phase 2 ZUPREME-1 results showing double-digit weight loss. This clinical milestone coincides with a September 2.]]></image:caption>
    </image:image>
  </url>
</urlset>